Tag - CytoAgents

In Her Own Words: Covid propels Teresa Whalen to improve cancer treatment

As Omnicron continues to take a toll on the country, we’re reminded how many women are on the front lines of health care. Some in the hospital setting, some as public health leaders and others, like Teresa Whalen, in the research lab where, as CEO of CytoAgents, she leads a team of world-renowned clinical drug development experts and scientific advisory board members to find treatments for Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. […]

EY Announces 27 Women Founders Selected for the EY Entrepreneurial Winning Women™ North America Class of 2021

EY announces the 27 women founders selected for the EY Entrepreneurial Winning Women™ North America Class of 2021. The program, now in its 14th year, identifies ambitious women entrepreneurs who are leading thriving organizations and provides them with the access, advisors and resources needed to scale their companies to their full potential as market-leading innovators. Program engagement offers participants executive education and introductions to the vast EY global entrepreneurial ecosystem as well as the Entrepreneurial Winning Women community worldwide. […]

Virtual Venture & IP Conference panel highlights life science ventures and COVID

How are life science ventures leveraging their technologies to help mitigate the spread and virulence of the novel coronavirus? The Invent Penn State Venture & IP Conference panel “Life Science Ventures Addressing COVID-19” will explore this topic from 4:25-5:20 p.m. on Thursday, April 15. Registration for the all-virtual Invent Penn State Venture & IP Conference, happening April 15-16, is currently open to the public. Panel members include: Teresa Whalen – CEO, CytoAgents Inc.: As a biotech innovator, health care […]

CytoAgents looks forward to a big 2021 and beyond

Up next are two clinical trials, a phase-two clinical trial for GP1681 in the area of Covid-19 and a separate clinical that will determine how it works with CAR-T patients. It’s shaping up to be a busy year for Pittsburgh-based CytoAgents, an early stage pharmaceutical company based in Pittsburgh whose drug candidate. Read more >>

Meet AlphaLab Health’s inaugural class of companies

Innovation Works and Allegheny Health Network today announced seven companies selected for the inaugural class of AlphaLab Health, a newly created business accelerator the two organizations launched this year to provide promising health-care and life-sciences businesses with the resources and support they need to grow and thrive. CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system […]

CytoAgents Receives Second Round of NIH Funding to Accelerate Treatment for Cytokine Storm

CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2 million National Institutes of Health (NIH) grant, the second NIH grant in a year. Read more >>

Wolf Administration Highlights Development of Promising New Drug Candidate to Treat COVID-19

On Wednesday, Department of Community and Economic Development (DCED) Deputy Secretary Steve D’Ettorre and Ben Franklin Technology Partners Innovation Works Chief Executive Officer Richard Lunak joined Teresa Whalen, CEO of Pittsburgh-based CytoAgents, to highlight the development of a new COVID-19 treatment. “This exciting new development was made possible by the strong partnerships the Wolf Administration has fostered with our Ben Franklin Technology Partners and the companies they support, like CytoAgents,” said D’Ettorre. Read more >>